Middle-aged patients with type 2 diabetes mellitus may have languished on monotherapy or a stable therapy for a substantial period without reconsideration of comorbidities or current control of glycated hemoglobin A 1c (HbA 1c ). In many patients who lose glycemic control, postprandial hyperglycemia has not been addressed. This is especially true when HbA 1c levels are close to-but not at-goal. Glucagonlike peptide-1 receptor agonists are injectable agents that can be added to oral therapy to address postprandial hyperglycemia. These agents may be a useful alternative to insulin therapy as add-on therapy when dual oral therapy is no longer sufficient and additional glucose lowering is required. Compared with insulin, glucagon-like peptide-1 receptor agonists have provided comparable glucose lowering with less hypoglycemia and without weight gain.
The caveat is that GLP-1 receptor ago- As expected, GI adverse effects were more common with AGIs. 
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